The effects of smoking and obesity on serum lipids and ERF values : A study in volunteers living in Kilis region
[KİLİS'TE YAŞAYAN NORMAL KİLOLU VE OBEZ ERKEKLERDE SİGARA ALIŞKANLIĞININ SERUM LİPİDLERİ VE ERF DEĞERLERİNE ETKİSİ]
Abstract views: 61
/ 
PDF downloads: 62
DOI:
https://doi.org/10.58600/eurjther.19930401-1128Keywords:
Smoking, obesity, serum lipids, ERFAbstract
in this study, the effects of smoking habit on serum trigliseryde, total cholesterol, LDL- cholesterol, HDL-cholesterol, phospholipid and ERF (established risk factor) values were investigated in smoker male volunteers and in 46 (21 obese, 25 normal) non smokers. While in obese smokers serum triglyseryde, total cholesterol, LDL-cholesterol and phospholipid values were found to be high significantly, in normals this effects were minimal. HDL-cholesterol decreased significantly in obese smokers. Both onesity and smoking habit were found to be a factors which increase in ERF values.in conclusion although the smoking and obesity are two of several risk factors in atherosclerosis it might be thought that very important biochemical changes may occur in obese smokers.
Metrics
References
Batman F, Çopur S.: Sigaranın gastrointestinal sistem üzerine etkileri. Yeni Tıp Dergisi, 5(3): 19-22,1988.
Mimoğlu M.M.: Sigaranın sitematik etkileri üzerine yapılan araştırmalar. Türk Hijen ve Deneysel Biyoloji Dergisi, 43(2): 85-9, 1986.
Calverley PMA, Leggett RJ, Mc Eldery L, Flenley DC. Cigarette smoking and secondary polycytemia in hypoxic cor pulmonale. Am Rev Respi, Dis, 125: 507-10, 1982.
Benowisz NL, Hail SM, Hemin RI, Jacob P, Jones RT, Osman AL. Smokers of low yield cigarettes do not consume less nicotine. The New Engl J Med, 309(3): 139-41, 1983.
Chillar RK, Desforges JF. Red cell organic phosphates in patients with chronic renal failure on maintenance haemodialysis. British J Hematology, 26: 549-56, 1974.
Stedman RL. The chemical composotion of tobacco smoke. Chem Rev, 68: 153-207, 1968.
Akkuş t, Bakan N, Çığlı A, Şahin YN. Erzurum ve çevresinde sigara içen ve içmeyen sağlam şahıslarda eritrosit içi 2,3-difosfogliserat (2,3-DPG) seviyeleri. T Klin Araştırma, 9(1): 24-8, 1991.
Bureau MA, Shapott D, Berthiaume Y and et al. Maternal cigarette smoking and fetal oxygen transport: A study of P 50 2,3-DPG, total Hb, HcT and Tip I Hb in fetal blood. Pediatrics, 27(1): 22-6, 1983.
Yılmaz M. Gaziantep'te şişmanlık prevalansı ve halkın beslenme alışkanlığı üzerine bir çalışma. Gaziantep Üniversitesi Tıp Fakültesi Dergisi (baskıda).
Pollok ML; Wilmore JH. Exercise in health and disease. 2nd ed. USA: WB Sauders Co.1990:56.
Calbreath OF. Clinical chemistry. USA: WB Sauders Co. 1992:68.
Fosatti P, Prencipe 1. Serum triglyserides determined colorimetrically with an ehzyme that produce hydrogen peroxide. Clin Chem, 28(10): 2077-80, 1982.
Mc Gowan MW, Artiss JD. Peroxidase coupled method for the colorimetric deteımination of serum glyserides. Oin Chem, 29(3): 538-42, 1983.
Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic deteımination of total serum cholesterol. Oin Chem, 20(4):470-5, 1974. 15.LDL-cholesterol, PVS method, Boehringer Diagnostica, Geımany.
Assmann G, Schriewer H, Schmitz G, Hagele EO. HDL-cholesterol. Oin Chem, 29: 2026, 1983.
Takayama M, Itoh 5, Nagasaki T, Tanimizo 1. Oin Chem Acta 79(1):93, 1977.
Kutty KM, Jain R, Huang SN, Keaa K. Serum pseudocholinesterase: High density lipoprotein cholesterol as an index of risk for cardiovasculer disease. Clin Chem Acta 115: 55-61, 1981.
Jain R, Kutty KM, Huana SN, Kean K. Pseudocholinesterase/High Density Lipoprotein cholesterol ratio in serum of normal persons of hyperlipoproteinemies. Clin CheM, 29(6): 1031- 3, 1983.
Rafferty J, Norling R and et al. StatsWorks,Philadelphia: Dala Metrics İnc, 1985.
Gorrow AM eds. The moleculer basis of acquired disease USA: Ballaire-Tindal and WB Saunders Co. 1990: 584-5.
Çığlı A, Ünaldı M, Çağlayan A, Oz OY, Kaleli S. Obez kişilerde AKŞ, total kolesterol, HDL-kolesterol ve trigliser düzeyleri. S.Ü. Tıp Fakültesi Dergisi, 8 (3): 379-82, 1992.
Sodeman TT. Metabolic biochemistry. in: Sodeman WA Sodeman TM, eds. Pathologic physiology. USA : WB Saunders Co, 1985: 10. Çeviri: Karaca L. Metabolik biyokimya, fizyopatoloji. Ankara; Türkiye Klinikleri Yayınevi, 1991:26.
Guyton AC. Textbook of medical physiology, 7'th edd. USA: WB Saunders Co, 1983. Çeviri: Gökhan N, Çavuşoğlu H. Tıbbi Fizyoloji, türkçe 1. baskı, lstanbul: Merk yayıncılık, 1986: 1182- 274.
Alberti KG, Boucher BJ, Hitman GA, Taylor R. Diabetes mellitus. in: Cohen RD, Lewis B, Alberti KG, Denman AM, eds. The moleculer basis of acquired disease. USA: Baullaiıe-Tindal and WB Saunders Co, 1990: 801-25.
Görpe A ve Görpe U. Pratik endokronoloji. lstanbul: Ennete Matbası, 1987: 184-5.
Carlson LA, Bottiger IE. Riisk factors for ischemic heart disease in man and women. Acta Med Scand, 218: 207, 1985.
Castelli WP, Doyle JT, Gordon T, Romes CG. HDL-cholesterol and other lipids coronary heart disease the cooperative lipoprotein phenotyping study. Circulation, 55(5): 567-72, 1977.
Sankardeşoğlu M, Önder E, Sankardeşoğlu H. Ateroslerotik kalp hastalıklannda serum lipid parametreleri ve lipoprotein elektrofore7; değerlendirmeleri ile tanıya yaklaşım. Biyokimya Dergisi, 13(1): 75-82, 1988.
Abaoğlu C, Aleksanyan V. Teşhisten tedaviye. 8. baskı. lstanbul: Filiz Kitabevi, 1980:791.
Sonel A. Kardiyoloji. Ankara A.Ü. Tıp Fakültesi basımevi, 1976: 347.
Maderrisoğlu V, Tamur P. Aterosklerotik iskemik kalp hastalığı bulunan vakalarda serum lipidleri ve lipoprotein fraksiyonları. Biyokimya Dergisi, 1: 17-27, 1976.
Yücel G. HOL-kolesterol ve önemi. Akdeniz Üniversitesi Tıp Fakültesi Dergisi, 7(3-4): 109-13, 1990.
Ünaldı M, Çimen A, Soysal ST, Akın V. Ateroskerozlu hastalarda bazı lipid parametrelerinin değerlendirilmesi. Biyokimya Dergisi, 5(3) : 45-54, 1980.
Lipid research program. Lipid metabolism-Atherogenesis Bransch, National Heart, Lung and Blood lnstitue Bethesda, Maryland/USA. JAMA, 251(3), Jan 20, 1984.
Preston AM. Cigarette smoking nutritional implications. Prog Food Nutr Sci, 15(4): 183-217, 1991.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
